In our biomarker-defined subpopulation, we observed a 0.27 effect size on the EMACC cognitive scale after only 6 months (2). For directional context, this magnitude compares favorably to the 18-month ...
INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, presents the following letter to investors from David Moss, CEO: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results